- Home
- CGC vs FDMT Comparison
CGC vs FDMT Comparison
Compare CGC & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGC | FDMT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.6M | 476.9M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CGC | FDMT |
|---|---|---|
| Price | $1.19 | $9.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | N/A | ★ $34.13 |
| AVG Volume (30 Days) | ★ 10.9M | 688.8K |
| Earning Date | 05-09-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.75 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,759,000.00 | $37,000.00 |
| Revenue This Year | $6.79 | $21,227.03 |
| Revenue Next Year | $7.34 | $161.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $2.24 |
| 52 Week High | $2.38 | $12.34 |
Technical Indicators
Market Signals| Indicator | CGC | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 54.36 |
| Support Level | $1.02 | $8.75 |
| Resistance Level | $1.15 | $9.78 |
| Average True Range (ATR) | 0.06 | 0.58 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 80.95 | 55.56 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.